Cilansetron
chemical compound
Cilansetron is an experimental drug that is a 5-HT3 antagonist under development by Solvay Pharmaceuticals.
5-HT3 receptors are responsible for causing many things from nausea to excess bowel movements. In conditions such as irritable bowel syndrome (IBS), the receptors have become faulty or oversensitive. 5-HT3 antagonists work by blocking the nervous and chemical signals from reaching these receptors.
Studies have shown that the drug can improve quality of life in men and women with diarrhea-predominant IBS. Cilansetron is the first 5-HT antagonist specifically designed for IBS that is effective in men as well as women.
In 2005, Solvay received response from the U.S. Food and Drug Administration that cilansertron is not approvable without additional clinical trials; further development has been discontinued.
This brief starts where responsible research should: with the source description of “Cilansetron” as chemical compound. Everything that follows is an evidence route, not borrowed authority.
Why this record matters
The subject matters to the science & nature register because the source frames it as chemical compound. Its deeper value depends on whether names, dates, institutions and citations support that framing.
Stable identifiers, scientific names and standards terminology offer the best bridge between this overview and specialist evidence. The source revision retrieved here is dated Jan 2, 2026. The linked authority identifier is Q5119931. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2005.
A general summary may omit uncertainty, sample limits or methodological disagreement that is explicit in the technical record. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Cilansetron”, its source revision and the description used here.
- Expand the search: follow Cilansetron primary sources, Cilansetron archive and Cilansetron research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Cilansetron”?
- Has classification or technical consensus changed since the cited source?
- Is the terminology current, historical or disputed?
Search terms from this dossier
This entry incorporates text from “Cilansetron” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.